{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:05:40Z","timestamp":1785391540345,"version":"3.55.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.xphs.2024.10.043","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:53:06Z","timestamp":1730422386000},"page":"566-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vehicle effect on in-vitro and in-vivo performance of spray-dried dispersions"],"prefix":"10.1016","volume":"114","author":[{"given":"Marika","family":"Nespi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8061-5445","authenticated-orcid":false,"given":"Shu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2551-7948","authenticated-orcid":false,"given":"Yimin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Castleberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2024.10.043_bib0001","doi-asserted-by":"crossref","unstructured":"Gao Y., Gesenberg C., Zheng W. Developing Solid Oral Dosage Forms (Second Edition). Part III: Des, Dev Scale-Up Formul Manuf Process. Published online 2017:455\u2013495. doi:10.1016\/b978-0-12-802447-8.00017-0","DOI":"10.1016\/B978-0-12-802447-8.00017-0"},{"issue":"6","key":"10.1016\/j.xphs.2024.10.043_bib0002","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10.1016\/j.xphs.2024.10.043_bib0003","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/bjp.2008.280","article-title":"Principles of safety pharmacology","volume":"154","author":"Pugsley","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.xphs.2024.10.043_bib0004","doi-asserted-by":"crossref","unstructured":"Lakshmanan M. Introduction to Basics of Pharmacology and Toxicology, Volume 3 : Experimental Pharmacology : Research Methodology and Biostatistics. Springer, Singapore. Published online 2022:625\u2013648. https:\/\/doi.org\/10.1007\/978-981-19-5343-9_48.","DOI":"10.1007\/978-981-19-5343-9_48"},{"key":"10.1016\/j.xphs.2024.10.043_bib0005","doi-asserted-by":"crossref","unstructured":"Meibohm B. Pharmacokinetics and Pharmacodynamics of Biotech Drugs. Wiley Online Library. Published online 2010:1\u201313. https:\/\/doi.org\/10.1002\/9783527609628.ch1","DOI":"10.1002\/9783527609628.ch1"},{"issue":"15\u201316","key":"10.1016\/j.xphs.2024.10.043_bib0006","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.drudis.2012.03.016","article-title":"Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure","volume":"17","author":"Higgins","year":"2012","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.xphs.2024.10.043_bib0007","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/1568026013395128","article-title":"Assessing the potential toxicity of new pharmaceuticals","volume":"1","author":"Johnson","year":"2001","journal-title":"Curr Top Med Chem"},{"issue":"5","key":"10.1016\/j.xphs.2024.10.043_bib0008","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3390\/life13051099","article-title":"Advancement in solubilization approaches: a step towards bioavailability enhancement of poorly soluble drugs","volume":"13","author":"Kumari","year":"2023","journal-title":"Life"},{"issue":"9","key":"10.1016\/j.xphs.2024.10.043_bib0009","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1002\/jps.24391","article-title":"Rate- and extent-limiting factors of oral drug absorption: theory and applications","volume":"104","author":"Sugano","year":"2015","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2024.10.043_bib0010","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1002\/jps.24199","article-title":"Oral Delivery of Highly Lipophilic Poorly Water-Soluble Drugs: spray-Dried Dispersions to Improve Oral Absorption and Enable High-Dose Toxicology Studies of a P2Y1 Antagonist","volume":"103","author":"Chen","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.10.043_bib0011","series-title":"Pharmaceutical Suspensions, From Formulation Development to Manufacturing","first-page":"265","author":"Gupta","year":"2009"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.043_bib0012","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3390\/pharmaceutics15030887","article-title":"Evaluation of pharmacobezoar formation from suspensions of spray-dried amorphous solid dispersions: an MRI study in rats","volume":"15","author":"Gierke","year":"2023","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.xphs.2024.10.043_bib0013","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1517\/17425255.2013.840291","article-title":"Vehicle selection for nonclinical oral safety studies","volume":"9","author":"Thackaberry","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.xphs.2024.10.043_bib0014","doi-asserted-by":"crossref","unstructured":"Leung D.H., Daublain P., Hu M., Feng K. Oral Formulation Roadmap from Early Drug Discovery to Development. Published online 2017:139\u2013164. doi:10.1002\/9781118907894.ch6","DOI":"10.1002\/9781118907894.ch6"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.043_bib0015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jconrel.2011.07.003","article-title":"Recent advances and novel strategies in pre-clinical formulation development: an overview","volume":"156","author":"Shah","year":"2011","journal-title":"J Control Rel"},{"issue":"5","key":"10.1016\/j.xphs.2024.10.043_bib0016","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1208\/s12249-014-0156-1","article-title":"Preclinical formulations: insight, strategies, and practical considerations","volume":"15","author":"Shah","year":"2014","journal-title":"AAPS PharmSciTech"},{"issue":"9","key":"10.1016\/j.xphs.2024.10.043_bib0017","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3390\/biomedicines10092055","article-title":"Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics","volume":"10","author":"Bhalani","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.xphs.2024.10.043_bib0018","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1208\/s12248-012-9383-0","article-title":"Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II\/IV compounds","volume":"14","author":"Kesisoglou","year":"2012","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.043_bib0019","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cpt.1672","article-title":"Evaluating the role of solubility in oral absorption of poorly water-soluble drugs using physiologically-based pharmacokinetic modeling","volume":"107","author":"Fink","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.xphs.2024.10.043_bib0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ejps.2007.05.110","article-title":"When poor solubility becomes an issue: from early stage to proof of concept","volume":"31","author":"Stegemann","year":"2007","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.043_bib0021","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.apsb.2013.11.001","article-title":"Fundamental aspects of solid dispersion technology for poorly soluble drugs","volume":"4","author":"Huang","year":"2014","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"10.1016\/j.xphs.2024.10.043_bib0022","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4155\/tde.14.101","article-title":"Amorphous solid dispersions: a robust platform to address bioavailability challenges","volume":"6","author":"Newman","year":"2015","journal-title":"Ther Deliv"},{"issue":"2","key":"10.1016\/j.xphs.2024.10.043_bib0023","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.ddtec.2011.10.002","article-title":"The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate","volume":"9","author":"den","year":"2012","journal-title":"Drug Discov Today: Technol"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.043_bib0024","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/10717544.2019.1704940","article-title":"Mechanisms of increased bioavailability through amorphous solid dispersions: a review","volume":"27","author":"Schittny","year":"2020","journal-title":"Drug Deliv"},{"issue":"6","key":"10.1016\/j.xphs.2024.10.043_bib0025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1021\/mp800061r","article-title":"Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study","volume":"5","author":"Kennedy","year":"2008","journal-title":"Mol Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2024.10.043_bib0026","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/pharmaceutics16070958","article-title":"Investigation of stabilized amorphous solid dispersions to improve oral olaparib absorption","volume":"16","author":"Yun","year":"2024","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.xphs.2024.10.043_bib0027","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3109\/03639045.2012.727829","article-title":"Amorphous solid dispersion successfully improved oral exposure of ADX71943 in support of toxicology studies","volume":"39","author":"Ayad","year":"2013","journal-title":"Drug Dev Ind Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2024.10.043_bib0028","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/jps.24541","article-title":"Amorphous solid dispersions: utilization and challenges in drug discovery and development","volume":"104","author":"He","year":"2015","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.043_bib0029","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.xphs.2022.03.020","article-title":"Formulation and processing strategies which underpin susceptibility to matrix crystallization in amorphous solid dispersions","volume":"112","author":"Moseson","year":"2023","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2024.10.043_bib0030","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1021\/acs.molpharmaceut.5b00950","article-title":"Effect of water on molecular mobility and physical stability of amorphous pharmaceuticals","volume":"13","author":"Mehta","year":"2016","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2024.10.043_bib0031","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1002\/aic.11261","article-title":"A population balance model of the solution-mediated phase transition of citric acid","volume":"53","author":"F\u00e9votte","year":"2007","journal-title":"AIChE J"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.043_bib0032","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.xphs.2022.10.020","article-title":"Detecting crystallinity in amorphous solid dispersions using dissolution testing: considerations on properties of drug substance, drug product, and selection of dissolution media","volume":"112","author":"Purohit","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.10.043_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119925","article-title":"Physical stability of amorphous pharmaceutical solids: nucleation, crystal growth, phase separation and effects of the polymers","volume":"590","author":"Shi","year":"2020","journal-title":"Int J Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2024.10.043_bib0034","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.xphs.2015.10.008","article-title":"Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs","volume":"105","author":"Baghel","year":"2016","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2024.10.043_bib0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/pharmaceutics14020269","article-title":"Factors influencing the crystallization-onset time of metastable ASDs","volume":"14","author":"Wolbert","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.043_bib0036","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1021\/acs.molpharmaceut.2c00989","article-title":"Impact of crystal nuclei on dissolution of amorphous drugs","volume":"20","author":"Yao","year":"2023","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.043_bib0037","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1021\/acs.molpharmaceut.0c01157","article-title":"Crystals and crystallization in drug delivery design","volume":"18","author":"Taylor","year":"2021","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2024.10.043_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122495","article-title":"High-throughput kinetic turbidity analysis for determination of amorphous solubility and excipient screening for amorphous solid dispersions","volume":"631","author":"Fan","year":"2023","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2024.10.043_bib0039","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1023\/A:1007585403781","article-title":"Assessment of polymer-polymer interactions in blends of HPMC and film forming polymers by modulated temperature differential scanning calorimetry","volume":"17","author":"Nyamweya","year":"2000","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.043_bib0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1208\/s12249-021-02160-1","article-title":"Optimization of spray-drying parameters for formulation development at preclinical scale","volume":"23","author":"Nespi","year":"2021","journal-title":"AAPS PharmSciTech"},{"issue":"9","key":"10.1016\/j.xphs.2024.10.043_bib0041","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s11095-017-2188-1","article-title":"Controlled suspensions enable rapid determinations of intrinsic dissolution rate and apparent solubility of poorly water-soluble compounds","volume":"34","author":"Andersson","year":"2017","journal-title":"Pharm Res"},{"issue":"9","key":"10.1016\/j.xphs.2024.10.043_bib0042","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1021\/acs.molpharmaceut.5b00409","article-title":"Long-term amorphous drug stability predictions using easily calculated, predicted, and measured parameters","volume":"12","author":"Nurzy\u0144ska","year":"2015","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2024.10.043_bib0043","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/B:PHAM.0000016235.32639.23","article-title":"Solubilizing excipients in oral and injectable formulations","volume":"21","author":"Strickley","year":"2004","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2024.10.043_bib0044","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1021\/mp500504q","article-title":"Preclinical dose number and its application in understanding drug absorption risk and formulation design for preclinical species","volume":"12","author":"Wuelfing","year":"2015","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2024.10.043_bib0045","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1021\/acs.molpharmaceut.1c00477","article-title":"Mechanistic investigation of drug supersaturation in the presence of polysorbates as solubilizing additives by solution nuclear magnetic resonance spectroscopy","volume":"18","author":"Lu","year":"2021","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2024.10.043_bib0046","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1021\/js950534b","article-title":"Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization","volume":"85","author":"Loftsson","year":"1996","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2024.10.043_bib0047","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/10915810600961531","article-title":"Nonclinical vehicle use in studies by multiple routes in multiple species","volume":"25","author":"Gad","year":"2006","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.xphs.2024.10.043_bib0048","unstructured":"M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Guidance for Industry. https:\/\/www.fda.gov"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.043_bib0049","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.yrtph.2009.05.015","article-title":"High dose selection in general toxicity studies for drug development: a pharmaceutical industry perspective","volume":"54","author":"Buckley","year":"2009","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2024.10.043_bib0050","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jps.23031","article-title":"Assessing the performance of amorphous solid dispersions","volume":"101","author":"Newman","year":"2012","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2024.10.043_bib0051","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1007\/s11095-017-2265-5","article-title":"Phase behavior of ritonavir amorphous solid dispersions during hydration and dissolution","volume":"34","author":"Purohit","year":"2017","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.xphs.2024.10.043_bib0052","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.xphs.2020.12.033","article-title":"Physical stability and dissolution of lumefantrine amorphous solid dispersions produced by spray anti-solvent precipitation","volume":"110","author":"Bhujbal","year":"2021","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2024.10.043_bib0053","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/17425247.2017.1230099","article-title":"Supersaturation and crystallization: non-equilibrium dynamics of amorphous solid dispersions for oral drug delivery","volume":"14","author":"Kawakami","year":"2017","journal-title":"Expert Opin Drug Del"},{"issue":"12","key":"10.1016\/j.xphs.2024.10.043_bib0054","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11095-019-2718-0","article-title":"Characterization of phase transformations for amorphous solid dispersions of a weakly basic drug upon dissolution in biorelevant media","volume":"36","author":"Elkhabaz","year":"2019","journal-title":"Pharmaceut Res"},{"key":"10.1016\/j.xphs.2024.10.043_bib0055","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2019.01.039","article-title":"Congruent release of drug and polymer: a \u201csweet spot\u201d in the dissolution of amorphous solid dispersions","volume":"298","author":"Saboo","year":"2019","journal-title":"J Control Rel"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.043_bib0056","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1021\/acs.molpharmaceut.2c00895","article-title":"Impact of gastric pH variations on the release of amorphous solid dispersion formulations containing a weakly basic drug and enteric polymers","volume":"20","author":"Nguyen","year":"2023","journal-title":"Mol Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2024.10.043_bib0057","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s11095-016-1913-5","article-title":"Leaching of lopinavir amorphous solid dispersions in acidic media","volume":"33","author":"Li","year":"2016","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2024.10.043_bib0058","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1021\/acs.molpharmaceut.3c01106","article-title":"Interplay of drug\u2013polymer interactions and release performance for HPMCAS-based amorphous solid dispersions","volume":"21","author":"Bapat","year":"2024","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2024.10.043_bib0059","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jconrel.2018.04.014","article-title":"Tailoring supersaturation from amorphous solid dispersions","volume":"279","author":"Li","year":"2018","journal-title":"J Control Rel"},{"issue":"12","key":"10.1016\/j.xphs.2024.10.043_bib0060","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1021\/acs.molpharmaceut.9b01025","article-title":"Insights into the dissolution behavior of ledipasvir\u2013copovidone amorphous solid dispersions: role of drug loading and intermolecular interactions","volume":"16","author":"Que","year":"2019","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2024.10.043_bib0061","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1021\/acs.molpharmaceut.2c00892","article-title":"Dissolution mechanisms of amorphous solid dispersions: role of drug load and molecular interactions","volume":"20","author":"Deac","year":"2023","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2024.10.043_bib0062","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1943","article-title":"Understanding the effect of hydroxypropyl-\u03b2-cyclodextrin on fenebrutinib absorption in an itraconazole\u2013fenebrutinib drug\u2013drug interaction study","volume":"108","author":"Durk","year":"2020","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235492400491X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235492400491X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T01:36:45Z","timestamp":1734745005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235492400491X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S002235492400491X"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.10.043","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vehicle effect on in-vitro and in-vivo performance of spray-dried dispersions","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}